FDA label 77215d87-ad22-4169-bd5f-a453f10b21ef

5 WARNINGS AND PRECAUTIONS 5.1 Worsening of BPH and Potential Risk of Prostate Cancer Patients with BPH treated with androgens are at an increased risk for worsening of signs and symptoms of BPH. Patients treated with androgens may be at increased risk for prostate cancer. Evaluation of the patient for prostate cancer prior to initiating and during treatment with androgens is appropriate [see Warnings and Precaution (5.9), Adverse Reactions (6.1), and Nonclinical Toxicology (13.1)]. Increases in serum PSA from baseline values were seen in approximately 18% of individuals in an open label study of 162 hypogonadal men treated with AndroGel for up to 42 months. Most of these increases were seen within the first year of therapy [see Contraindications (4), Warnings and Precautions (5.9), Adverse Reactions (6), and Nonclinical Toxicology (13.1)]. 5.2 Potential for Testosterone Transfer to Others Transfer of testosterone to others (including women and children) can occur when vigorous skin-to-skin contact is made with the application site [see Clinical Studies (14.3)] . The following precautions are recommended to minimize potential transfer of testosterone from AndroGel-treated skin to another person: Patients should wash their hands immediately with soap and water after application of AndroGel. Patients should cover the application site(s) with clothing after the gel has dried (e.g., a shirt). In the event that unwashed or unclothed skin to which AndroGel has been applied does come in direct contact with the skin of another person, the general area of contact on the other person should be washed with soap and water as soon as possible. In vitro studies show that residual testosterone is removed from the skin surface by washing with soap and water. Women and children should avoid skin contact with AndroGel application sites in males. Changes in body hair distribution, significant increase in acne, or other signs of virilization should be brought to the attention of a physician. AndroGel may cause fetal harm in a pregnant woman due to virilization of a female fetus [see Use in Specific Populations (8.1)]. 5.3 Use in Women Due to lack of controlled evaluations in women and potential virilizing effects, AndroGel is not indicated for use in women [see Use in Specific Populations (8.1, 8.3)]. 5.4 Potential for Adverse Effects on Spermatogenesis At large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count. 5.5 Hepatic Adverse Effects Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. AndroGel is not known to produce these adverse effects. There are rare reports of hepatocellular carcinoma in patients receiving long-term oral therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases. 5.6 Edema Drugs in the androgen class may promote retention of sodium and water. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease [see Adverse Reactions (6.2)]. 5.7 Gynecomastia Gynecomastia may develop and may persist in patients being treated with androgens, including AndroGel, for hypogonadism. 5.8 Sleep Apnea The treatment of hypogonadal men with testosterone products may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung diseases [see Adverse Reactions (6.2)] . 5.9 Laboratory Tests Increases in hematocrit, reflective of increases in red blood cell mass, may require lowering or discontinuation of testosterone. Increase in red blood cell mass may increase the risk for a thromboembolic event. Changes in serum lipid profile may require dose adjustment or discontinuation of testosterone therapy. Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. Androgens should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Regular monitoring of serum calcium concentrations is recommended in these patients. 5.10 Flammable until Dry Alcohol Based Products including AndroGel are flammable; therefore avoid fire, flame or smoking until the gel has dried.

6 ADVERSE REACTIONS 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials in Hypogonadal Men Table 2 shows the incidence of all adverse events judged by the investigator to be at least possibly related to treatment with AndroGel and reported by >1% of patients in a 180 Day, Phase 3 study. Table 2: Adverse Events Possibly, Probably or Definitely Related to Use of AndroGel in the 180-Day Controlled Clinical Trial ___________ Dose of AndroGel ___ Adverse Event ____________________ _ __________ _ _________5 g________ _____ ______7.5 g________________ ________ 10 g____________ _______N = 77 _______ ____ N = 40 ________N = 78___________ Acne 1% 3% 8% Alopecia 1% 0% 1% Application Site Reaction 5% 3% 4% Asthenia 0% 3% 1% Depression 1% 0% 1% Emotional Lability 0% 3% 3% Gynecomastia 1% 0% 3% Headache 4% 3% 0% Hypertension 3% 0% 3% Lab Test Abnormal * 6% 5% 3% Libido Decreased 0% 3% 1% Nervousness 0% 3% 1% Pain Breast 1% 3% 1% Prostate Disorder ** 3% 3% 5% Testis Disorder *** 3% 0% 0% * Lab test abnormal occurred in nine patients with one or more of the following events reported: elevated hemoglobin or hematocrit, hyperlipidemia, elevated triglycerides, hypokalemia, decreased HDL, elevated glucose, elevated creatinine, elevated total bilirubin. ** Prostate disorders included five patients with enlarged prostate, one with BPH, and one with elevated PSA results. *** Testis disorders were reported in two patients: one with left varicocele and one with slight sensitivity of left testis. Other less common adverse reactions, reported in fewer than 1% of patients included: amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation. In this 180 day clinical trial, skin reactions at the site of application were reported with AndroGel, but none was severe enough to require treatment or discontinuation of drug. Six patients (4%) in this trial had adverse events that led to discontinuation of AndroGel. These events included: cerebral hemorrhage, convulsion (neither of which were considered related to AndroGel administration), depression, sadness, memory loss, elevated prostate specific antigen, and hypertension No AndroGel patient discontinued due to skin reactions. In a separate uncontrolled pharmacokinetic study of 10 patients, two had adverse events associated with AndroGel; these were asthenia and depression in one patient and increased libido and hyperkinesia in the other. In a 3 year, flexible dose, extension study, the incidence of all adverse events judged by the investigator to be at least possibly related to treatment with AndroGel and reported by greater than 1% of patients is shown in Table 3. Table 3: Adverse Events Possibly, Probably or Definitely Related to Use of AndroGel in the 3 Year, Flexible Dose, Extension Study Adverse Event Percent of Subjects (N = 162) Lab Test Abnormal+ 9.3 Skin dry 1.9 Application Site Reaction 5.6 Acne 3.1 Pruritus 1.9 Enlarged Prostate 11.7 Carcinoma of Prostate 1.2 Urinary Symptoms* 3.7 Testis Disorder** 1.9 Gynecomastia 2.5 Anemia 2.5 + Lab test abnormal occurred in 15 patients with one or more of the following events reported: elevated AST, elevated ALT, elevated testosterone, elevated hemoglobin or hematocrit, elevated cholesterol, elevated cholesterol/LDL ratio, elevated triglycerides, elevated HDL, elevated serum creatinine.* Urinary symptoms included nocturia, urinary hesitancy, urinary incontinence, urinary retention, urinary urgency and weak urinary stream. ** Testis disorders included three patients. There were two with a non-palpable testis and one with slight right testicular tenderness. Two patients reported serious adverse events considered possibly related to treatment: deep vein thrombosis (DVT) and prostate disorder requiring a transurethral resection of the prostate (TURP). Discontinuation for adverse events in this study included: two patients with application site reactions, one with kidney failure, and five with prostate disorders (including increase in serum PSA in 4 patients, and increase in PSA with prostate enlargement in a fifth patient). Increases in Serum PSA Observed in Clinical Trials of Hypogonadal Men During the initial 6-month study, the mean change in PSA values had a statistically significant increase of 0.26 ng/mL. Serum PSA was measured every 6 months thereafter in the 162 hypogonadal men on AndroGel in the 3-year extension study. There was no additional statistically significant increase observed in mean PSA from 6 months through 36 months. However, there were increases in serum PSA observed in approximately 18% of individual patients. The overall mean change from baseline in serum PSA values for the entire group from month 6 to 36 was 0.11 ng/mL. Twenty-nine patients (18%) met the per-protocol criterion for increase in serum PSA, defined as greater than 2X the baseline or any single serum PSA greater than 6 ng/mL. Most of these (25/29) met this criterion by at least doubling of their PSA from baseline. In most cases where PSA at least doubled (22/25), the maximum serum PSA value was still less than 2 ng/mL. The first occurrence of a pre-specified, post-baseline increase in serum PSA was seen at or prior to Month 12 in most of the patients who met this criterion (23 of 29; 79%). Four patients met this criterion by having a serum PSA greater than 6 ng/mL and in these, maximum serum PSA values were 6.2 ng/mL, 6.6 ng/mL, 6.7 ng/mL, and 10.7 ng/mL. In two of these patients, prostate cancer was detected on biopsy. The first patient's PSA levels were 4.7 ng/mL and 6.2 ng/mL at baseline and at Month 6/Final, respectively. The second patient's PSA levels were 4.2 ng/mL, 5.2 ng/mL, 5.8 ng/mL, and 6.6 ng/mL at baseline, Month 6, Month 12, and Final, respectively. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of AndroGel. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypogonadal Men Table 4 includes adverse reactions that have been identified postmarketing. Table 4: Adverse Drug Reactions from Postmarketing Experience of AndroGel by MedDRA System Organ Class Blood and the lymphatic system disorders: Elevated Hgb, Hct (polycythemia) Endocrine disorders: Hirsutism Gastrointestinal disorders: Nausea General disorders and administration site reactions: Asthenia, edema, malaise Genitourinary disorders: Impaired urination Hepatobiliary disorders: Abnormal liver function tests (e.g. transaminases, elevated GCTP, bilirubin) Investigations: Elevated PSA, electrolyte changes (nitrogen, calcium, potassium, phosphorus, sodium), changes in serum lipids (hyperlipidemia, elevated triglycerides, decreased HDL), impaired glucose tolerance, fluctuating testosterone levels, weight increase Neoplasms benign, malignant and unspecified (cysts and polyps): Prostate cancer Nervous system: Headache, dizziness, sleep apnea, insomnia Psychiatric disorders: Depression, emotional lability, decreased libido, nervousness, hostility, amnesia, anxiety Reproductive system and breast disorders: Gynecomastia, mastodynia, prostatic enlargement, testicular atrophy, oligospermia, priapism (frequent or prolonged erections) Respiratory disorders: Dyspnea Skin and subcutaneous tissue disorders: Acne, alopecia, application site reaction (pruritus, dry skin, erythema, rash, discolored hair, paresthesia), sweating Vascular disorders: Hypertension, vasodilation (hot flushes)

<table width="0.000" ID="id_5e07c300-6bf9-4ca1-9952-211370325d23"> <caption ID="id_080dec30-b9ea-448f-b13f-bb6edf410d53">Table 2: Adverse Events Possibly, Probably or Definitely Related to Use of AndroGel in the 180-Day Controlled Clinical Trial</caption> <col/> <col/> <col/> <col/> <col/> <tbody> <tr ID="id_20d3a696-45f5-4662-a2ba-0ce1c8637c45" styleCode="Toprule"> <td align="left" valign="top"> </td> <td align="left" valign="top" styleCode="Toprule"> </td> <td align="left" valign="top" styleCode="Toprule"> <content styleCode="underline"> </content> </td> <td align="left" valign="top" styleCode="Toprule"> <content styleCode="underline">___________ </content> <content styleCode="underline">Dose of AndroGel</content> <content styleCode="bold"> <content styleCode="underline"> <content styleCode="underline"> ___ </content> </content> </content> </td> <td align="left" valign="top"> <content styleCode="underline"> </content> </td> </tr> <tr ID="id_b8ec4b08-7ad7-45dc-85eb-a9861800b78e"> <td align="left" valign="top"> </td> <td align="left" valign="top">Adverse Event </td> <td align="left" valign="top"> </td> <td align="left" valign="top"> <content styleCode="underline"> </content> </td> <td align="left" valign="top"> <content styleCode="underline"> </content> </td> </tr> <tr ID="id_dac0fcf9-b3d9-4c5a-9914-49ce14173417"> <td align="left" valign="top"> <content styleCode="underline">____________________</content> </td> <td align="left" valign="top"> <content styleCode="underline">_ __________</content>_ </td> <td align="left" valign="top"> <content styleCode="underline">_________5 g________</content> </td> <td align="left" valign="top"> <content styleCode="underline">_____ ______7.5 g________________</content> </td> <td align="left" valign="top"> <content styleCode="underline">________ 10 g____________</content> </td> </tr> <tr ID="id_1ea51e73-1af9-416c-b17d-a7246a164350"> <td align="left" valign="top"> <content styleCode="underline"> </content> </td> <td align="left" valign="top"> <content styleCode="underline"> </content> </td> <td align="left" valign="top"> <content styleCode="underline">_______N = 77 </content> </td> <td align="left" valign="top"> <content styleCode="underline">_______ ____ N = 40 </content> </td> <td align="left" valign="top"> <content styleCode="underline">________N = 78___________</content> </td> </tr> <tr ID="id_07798f45-f28d-4c0a-b1ad-69312494cdc8"> <td align="left" valign="top">Acne </td> <td align="left" valign="top"> </td> <td align="left" valign="top">1% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">8% </td> </tr> <tr ID="id_f5a9abff-a443-4551-8bf8-1e4b6e9193e9"> <td align="left" valign="top">Alopecia </td> <td align="left" valign="top"> </td> <td align="left" valign="top">1% </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">1% </td> </tr> <tr ID="id_d4a99f08-476f-4794-8b12-5b0244ca5673"> <td align="left" valign="top">Application Site Reaction </td> <td align="left" valign="top"> </td> <td align="left" valign="top">5% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">4% </td> </tr> <tr ID="id_293b02ba-1592-483b-ba97-5213180e984a"> <td align="left" valign="top">Asthenia </td> <td align="left" valign="top"> </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">1% </td> </tr> <tr ID="id_1dd054e4-4ffc-4d4c-a457-3dc4679aeb5d"> <td align="left" valign="top">Depression </td> <td align="left" valign="top"> </td> <td align="left" valign="top">1% </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">1% </td> </tr> <tr ID="id_fa09654b-116a-475a-9eb7-ab267a1a01ae"> <td align="left" valign="top">Emotional Lability </td> <td align="left" valign="top"> </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">3% </td> </tr> <tr ID="id_dd8bc6f1-2abe-444e-970a-9f672574a02f"> <td align="left" valign="top">Gynecomastia </td> <td align="left" valign="top"> </td> <td align="left" valign="top">1% </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">3% </td> </tr> <tr ID="id_1d14993f-a622-476f-ad64-37d5c41771d8"> <td align="left" valign="top">Headache </td> <td align="left" valign="top"> </td> <td align="left" valign="top">4% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">0% </td> </tr> <tr ID="id_952b5c45-74ab-44d7-9894-dcfd93e641ee"> <td align="left" valign="top">Hypertension </td> <td align="left" valign="top"> </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">3% </td> </tr> <tr ID="id_df8f285a-7dc3-4315-97f1-d7add285a963"> <td align="left" valign="top">Lab Test Abnormal * </td> <td align="left" valign="top"> </td> <td align="left" valign="top">6% </td> <td align="left" valign="top">5% </td> <td align="left" valign="top">3% </td> </tr> <tr ID="id_432a751b-5bc1-4bf7-8cf8-a0cf59d931a9"> <td align="left" valign="top">Libido Decreased </td> <td align="left" valign="top"> </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">1% </td> </tr> <tr ID="id_32d79985-1657-4bb8-b3a9-0593f7e03db8"> <td align="left" valign="top">Nervousness </td> <td align="left" valign="top"> </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">1% </td> </tr> <tr ID="id_f39095f6-69a5-4242-b8df-b918f176a0df"> <td align="left" valign="top">Pain Breast </td> <td align="left" valign="top"> </td> <td align="left" valign="top">1% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">1% </td> </tr> <tr ID="id_ff62adae-a592-41d3-a752-54f8cfd70e79"> <td align="left" valign="top">Prostate Disorder ** </td> <td align="left" valign="top"> </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">5% </td> </tr> <tr ID="id_a26e7e9c-5f7e-4b8b-acdc-3ffbc96cd2aa" styleCode="Botrule"> <td align="left" valign="top">Testis Disorder *** </td> <td align="left" valign="top"> </td> <td align="left" valign="top">3% </td> <td align="left" valign="top">0% </td> <td align="left" valign="top">0% </td> </tr> </tbody> </table>

<table width="0.000" ID="id_348bd428-cd5b-4e86-b9c2-84d284043527"> <caption ID="id_f1910825-4e62-4fa8-8a16-08c58b33ed3b">Table 3: Adverse Events Possibly, Probably or Definitely Related to Use of AndroGel in the 3 Year, Flexible Dose, Extension Study</caption> <col/> <col/> <tbody> <tr ID="id_e96458e9-e38b-4f48-95a9-a4dc5433457f" styleCode="Toprule"> <td align="left" valign="top">Adverse Event </td> <td align="left" valign="top"> <content styleCode="underline">Percent of Subjects</content> (N = 162) </td> </tr> <tr ID="id_d682e08b-91ea-46e2-8fa5-164ae94e762c"> <td align="left" valign="top">Lab Test Abnormal+ </td> <td align="left" valign="top">9.3 </td> </tr> <tr ID="id_5c3609be-68de-43b7-9e02-6b601eebe862"> <td align="left" valign="top">Skin dry </td> <td align="left" valign="top">1.9 </td> </tr> <tr ID="id_8aad3b14-35d1-4cfa-b757-2d715be37f9d"> <td align="left" valign="top">Application Site Reaction </td> <td align="left" valign="top">5.6 </td> </tr> <tr ID="id_0f308277-741b-4319-b074-21babf336e36"> <td align="left" valign="top">Acne </td> <td align="left" valign="top">3.1 </td> </tr> <tr ID="id_e59c878d-7e92-45ce-8e14-c6a14f48c27e"> <td align="left" valign="top">Pruritus </td> <td align="left" valign="top">1.9 </td> </tr> <tr ID="id_c7b35822-434e-49f1-ad61-dabc2776b3da"> <td align="left" valign="top">Enlarged Prostate </td> <td align="left" valign="top">11.7 </td> </tr> <tr ID="id_2fcbe70a-29f3-405e-9026-198b2054c2cf"> <td align="left" valign="top">Carcinoma of Prostate </td> <td align="left" valign="top">1.2 </td> </tr> <tr ID="id_efd92c77-4b35-41ba-80bc-fdd5c7fec1cf"> <td align="left" valign="top">Urinary Symptoms* </td> <td align="left" valign="top">3.7 </td> </tr> <tr ID="id_e90af91a-79d4-4e13-b47e-4ea26f54ac82"> <td align="left" valign="top">Testis Disorder** </td> <td align="left" valign="top">1.9 </td> </tr> <tr ID="id_0b5548e0-0d7a-4bfb-8efc-8d9bece1943e"> <td align="left" valign="top">Gynecomastia </td> <td align="left" valign="top">2.5 </td> </tr> <tr ID="id_87f29e6d-29e8-4f32-96d6-cbcae991483f" styleCode="Botrule"> <td align="left" valign="top">Anemia </td> <td align="left" valign="top">2.5 </td> </tr> </tbody> </table>

<table width="0.000" ID="id_3403cc5c-7156-4352-af6f-40533cf71f1a"> <caption ID="id_10471bd6-3cf9-432d-b672-0db2ebfb042c">Table 4: Adverse Drug Reactions from Postmarketing Experience of AndroGel by MedDRA System Organ Class</caption> <col/> <col/> <tbody> <tr ID="id_c69e4d56-2b60-4d94-9c82-bfd1fc7e9c1f" styleCode="Toprule"> <td align="left" valign="top">Blood and the lymphatic system disorders:</td> <td align="left" valign="top">Elevated Hgb, Hct (polycythemia)</td> </tr> <tr ID="id_0e275b5f-c59d-44ba-a9d5-2643823f403e"> <td align="left" valign="top">Endocrine disorders:</td> <td align="left" valign="top">Hirsutism</td> </tr> <tr ID="id_80978677-12e8-4ebe-b4db-e25272a414b1"> <td align="left" valign="top">Gastrointestinal disorders:</td> <td align="left" valign="top">Nausea</td> </tr> <tr ID="id_300b3684-96a1-44c3-9fca-47fa332cd396"> <td align="left" valign="top">General disorders and administration site reactions:</td> <td align="left" valign="top">Asthenia, edema, malaise</td> </tr> <tr ID="id_3d47117d-6151-4564-a2ca-10ea5a197949"> <td align="left" valign="top">Genitourinary disorders:</td> <td align="left" valign="top">Impaired urination</td> </tr> <tr ID="id_5746aa11-5b9d-4a8a-af14-0d04a120ca9b"> <td align="left" valign="top">Hepatobiliary disorders:</td> <td align="left" valign="top">Abnormal liver function tests (e.g. transaminases, elevated GCTP, bilirubin)</td> </tr> <tr ID="id_dc924bf7-d80b-408b-baeb-874227d2697c"> <td align="left" valign="top">Investigations:</td> <td align="left" valign="top">Elevated PSA, electrolyte changes (nitrogen, calcium, potassium, phosphorus, sodium), changes in serum lipids (hyperlipidemia, elevated triglycerides, decreased HDL), impaired glucose tolerance, fluctuating testosterone levels, weight increase</td> </tr> <tr ID="id_6cd8bd08-d364-4e8f-ad17-62718d42fa13"> <td align="left" valign="top">Neoplasms benign, malignant and unspecified (cysts and polyps):</td> <td align="left" valign="top">Prostate cancer</td> </tr> <tr ID="id_25979d11-bd02-4c20-8f64-3c7efb4778c3"> <td align="left" valign="top">Nervous system:</td> <td align="left" valign="top">Headache, dizziness, sleep apnea, insomnia</td> </tr> <tr ID="id_f9dce82a-a877-4242-8769-ed3788d98344"> <td align="left" valign="top">Psychiatric disorders:</td> <td align="left" valign="top">Depression, emotional lability, decreased libido, nervousness, hostility, amnesia, anxiety</td> </tr> <tr ID="id_7b5cc662-005b-4480-8b17-ac58ea02131c"> <td align="left" valign="top">Reproductive system and breast disorders:</td> <td align="left" valign="top">Gynecomastia, mastodynia, prostatic enlargement, testicular atrophy, oligospermia, priapism (frequent or prolonged erections)</td> </tr> <tr ID="id_a67e11d6-a12f-4343-90e9-77a059d88533"> <td align="left" valign="top">Respiratory disorders:</td> <td align="left" valign="top">Dyspnea</td> </tr> <tr ID="id_067dffff-dfa1-46bf-a861-a778ed4aeb62"> <td align="left" valign="top">Skin and subcutaneous tissue disorders:</td> <td align="left" valign="top">Acne, alopecia, application site reaction (pruritus, dry skin, erythema, rash, discolored hair, paresthesia), sweating</td> </tr> <tr ID="id_cbf10ddd-638d-493b-beca-9a25babd5300" styleCode="Botrule"> <td align="left" valign="top">Vascular disorders:</td> <td align="left" valign="top">Hypertension, vasodilation (hot flushes)</td> </tr> </tbody> </table>